Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... the medical device industry gathers at Sales and Marketing Excellence 2010 ... device companies a solution to promote and sell in this highly regulated ... Maureen Shaffer ... "Sales-Friendly Compliant Content Communication: How to Score Wins for Sales, Marketing, and ...
... Georgia , May 20, 2010 , ... - Critical Care Pharmacology Course Promotes Patient ... ... than 1,300 healthcare organizations,has partnered with the American Association of Critical-Care Nurses (AACN) ...
Cached Medicine Technology:Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 2Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 3Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 2Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 3Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 4Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 5Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 6Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 7
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/22/2014)... visited the New Jersey Institute of Technology (NJIT) ... for the launch of the New Jersey Innovation ... new model for business innovation through the leveraging ... investment. U.S. Senator Cory Booker, Panasonic Corp. of ... Jersey Lieutenant Governor Kim Guadagno, New Jersey Secretary ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... NY, April 22, 2014Hemoglobin A1c is the standard measurement ... diabetes. Blood levels of A1c are typically measured every ... developed a data-based model that accurately estimates A1c using ... Diabetes Technology & Therapeutics ( DTT ), a ... article is available free on the DTT ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... HAVEN, Conn., May 29 ... today announced that an analysis of clinical data of ... myeloid leukemia (AML) would be presented in a poster ... Annual Meeting in Orlando, Florida.The poster (Abstract #7050) entitled ...
... Minimally Invasive Spine Surgery Provides Better Diagnosis and Treatment ... Kenneth L. Reed, M.D. performed the first revolutionary ... to treat acute and chronic back pain ... physicians are the only doctors performing the procedure in ...
... available for incontinence nowadays, an effective and easy solution ... incontinence. The main roadblock to that solution might just ... his condition. Dr. Peter Muench of Delaware Urologic Associates ... advises patients that full disclosure is the best policy ...
... Scottish Widows paid over £28m in critical illness cover claims between November ... due to non-disclosure, The three main reasons for claims - cancer, heart ... ... Scottish Widows, one of the most trusted brands in life insurance ...
... in a Series of Community Discussions on Improving Access ... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, ... roundtables as part of their Year of Affordable Healthcare ... at the YMCA San Francisco, aimed at raising awareness ...
... balloon also floated by President Clinton in 1993 to pay ... comes to finding a way to finance government-run health care, ... balloon echoing that of President Bill Clinton in 1993.The Obama ... spokesman for Obama Budget Director Peter Orszag, who was quoted ...
Cached Medicine News:Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 3Health News:Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 3Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 4Health News:Scottish Widows Releases Critical Illness Cover Claims Figures 2Health News:The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis 2Health News:ATR: Obama's VAT Trial Balloon Dusts Off Bill Clinton's 1993 Playbook 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: